Study record managers: refer to the Data Element Definitions if submitting registration or results information. It also helps stop the patient's immune system from rejecting the donor's cells. Giving NK cells from a related donor may kill the tumor cells.
More than a century ago, William Coley, a surgical oncologist from New York City, had the seemingly crazy notion that the body has an immune system that can be harnessed to fight cancer. After witnessing cancer regress in one of his patients after developing a skin infection, Coley developed a novel cancer treatment in which he injected more than 1, patients with a mixture of heat-killed bacteria. This week, the Food and Drug Administration FDA approved yet another immunotherapy: a combination of Opdivo nivolumab and Yervoy ipilimumab for people with a previously treated type of colorectal cancer, according to Bristol-Myers Squibb, the manufacturer of the drugs.
Recommend FPrime to your librarian or information manager to request an extended free trial for all users at your institution. User comments must be in English, comprehensible and relevant to the article under discussion. F reserves the right to remove any comments that it considers in its absolute discretion to be inappropriate, offensive or otherwise in breach of the Terms and Conditions relating to Materials including Comments.
In recent decades, tumor surveillance by the immune system and its impact on disease outcomes in cancer patients in general and in breast cancer BC patients in particular has been documented. Natural killer NK cells are central components of the innate immunity and existing data indicate that they play a role in preventing and controlling tumor growth and metastasis. Their biological significance was first recognized by their ability to exert direct cellular cytotoxicity without prior sensitization.
Currently, one of the most used strategies for the treatment of newly diagnosed patients with breast cancer is neoadjuvant chemotherapy based on the application of taxanes and anthracyclines. However, despite the high number of patients who develop a complete pathological clinical response, resistance and relapse following this therapy continue to be a clinical challenge. However, the role of NK cells in resistance to systemic therapy in breast cancer remains unclear. The present project aims to evaluate the gene expression profile of human NK cells in breast cancer tissue resistant to treatment with taxanes—anthracyclines.
Human NK lymphocytes are involved in antitumor immunity. The therapeutic potential of this population against cancers has stimulated their study and led to the discovery of several NK cell subsets, each of which is endowed with different immunoregulatory functions. We have previously reported that NK cell functions are profoundly altered in advanced breast cancer patients.
I n a first-of-its-kind clinical trial, a natural killer cell immunotherapy derived from induced pluripotent stem cells is being tested for safety in 64 patients with a variety of solid tumors. Kaufman collaborates with Fate Therapeutics, a biotech firm that developed the therapy, and researchers at the University of Minnesota to develop natural killer NK cell products including the one used in the study. NK cells are immune cells in the same family as T and B cells, and are very good at targeting cancer cells for destruction.